Takeda Secures First ASEAN Plasma Fractionation License in $30M Indonesia Deal

For Takeda’s plasma-derived therapies business, this license opens a new source of plasma and manufacturing capacity in Southeast Asia, diversifying its supply chain and potentially expanding its product portfolio for rare diseases like immunodeficiencies and hemophilia. The move reflects a strategic bet on emerging market biologics manufacturing.

In a landmark move announced on July 12, 2026, Takeda Pharmaceutical Company and the Indonesian Government have unveiled a multi-year collaboration to build a domestic plasma ecosystem for the production of plasma-derived medicinal products (PDMPs). According to Takeda and the Ministry of Health of the Republic of Indonesia, the initiative is anchored by the granting of a plasma fractionation license to Takeda — the first of its kind in the Association of Southeast Asian Nations (ASEAN) region. Takeda claims it will invest up to $30 million initially to establish the foundational infrastructure, including a pilot national plasma donation network. This collaboration, building on decades of Takeda’s presence in Indonesia, aims to enhance the country’s healthcare resilience and expand equitable access to lifesaving therapies for patients with conditions such as immunodeficiencies, hemophilia, and other rare diseases that depend on PDMPs.

“

From a financial perspective, Takeda’s commitment of $30 million is a modest outlay relative to its annual R&D budget (over $5 billion in recent years), but it signals a strategic bet on emerging markets.

From a strategic healthcare perspective, the partnership addresses a critical gap in Indonesia’s biopharmaceutical manufacturing capacity. PDMPs are derived from human plasma and require complex fractionation — the process of separating plasma into its therapeutic components — which has historically been concentrated in a few countries with advanced infrastructure. Indonesia, with a population of over 270 million, currently relies heavily on imported PDMPs, leaving it vulnerable to supply disruptions and price volatility. By establishing a domestic collection and fractionation capacity, the government aims to secure a sustainable supply of these essential medicines. Minister Budi Gunadi Sadikin emphasized that the initiative reflects Indonesia’s commitment to building strategic healthcare capabilities and ensuring sustainable access to innovative therapies. The project also aligns with the government’s broader health sovereignty agenda, which seeks to reduce dependency on foreign pharmaceuticals and strengthen the national health system against future pandemics.

For Takeda, the collaboration represents a significant expansion of its plasma-derived therapies business in Southeast Asia. The company, already a global leader in PDMPs with a portfolio that includes immunoglobulins, albumin, and coagulation factors, has been actively diversifying its plasma sourcing and manufacturing footprint. Indonesia offers a large, untapped donor population and a growing healthcare market. The fractionation license not only allows Takeda to collect plasma within Indonesia but also to process it locally, potentially creating a regional manufacturing hub. The initial $30 million investment is described as a phase one, with expectations of scaling up based on the success of the pilot network and regulatory framework. While the press release does not detail the timeline for commercial production, it suggests that the multi-year initiative could position Indonesia as a plasma science hub for ASEAN, catering to both domestic and regional demand.

Market observers note that this kind of public-private partnership could serve as a model for other middle-income countries seeking to build self-sufficiency in biologics. However, the success of the venture depends on several factors: the ability to establish a safe, voluntary plasma donation culture, robust regulatory oversight of fractionation facilities, and the economic viability of local production compared to importing finished products. The plasma donation network pilot will be a critical early test, as it involves public education, donor recruitment, and adherence to international quality standards. Additionally, the political and regulatory stability in Indonesia will influence the long-term sustainability of the investment.